All the above illustrated that the overexpression of ICAM1, THY1, and CXCR4 significantly implied adverse outcomes, whereas EPCAM implied more optimistic clinicopathological characteristics of GC patients. This evidence concerns the gene CXCR4 and gastric cancer.